Trials / Completed
CompletedNCT04086745
A Study of Baricitinib in Participants With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,317 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally. |
| DRUG | TNF Inhibitor | Administered SC |
Timeline
- Start date
- 2020-02-14
- Primary completion
- 2025-05-19
- Completion
- 2025-05-19
- First posted
- 2019-09-12
- Last updated
- 2025-07-17
Locations
119 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04086745. Inclusion in this directory is not an endorsement.